Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)’s share price traded down 2.7% during trading on Thursday . The stock traded as low as $8.50 and last traded at $8.54, with a volume of 59,818 shares traded. The stock had previously closed at $8.78.

Several equities analysts have commented on the stock. Leerink Swann restated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a research note on Sunday, April 24th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research note on Tuesday, July 12th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $15.94.

The stock has a 50 day moving average of $8.37 and a 200-day moving average of $8.65. The stock’s market capitalization is $616.54 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.03. Equities analysts anticipate that Adaptimmune Therapeutics PLC – will post ($1.12) earnings per share for the current year.

In other news, Director Orbimed Advisors Llc acquired 1,712,400 shares of Adaptimmune Therapeutics PLC – stock in a transaction that occurred on Tuesday, May 24th. The shares were acquired at an average price of $10.42 per share, with a total value of $17,843,208.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Charles Elliott Sigal acquired 45,000 shares of Adaptimmune Therapeutics PLC – stock in a transaction that occurred on Wednesday, May 18th. The shares were purchased at an average cost of $1.53 per share, for a total transaction of $68,850.00. Following the purchase, the director now directly owns 52,938 shares of the company’s stock, valued at approximately $80,995.14. The disclosure for this purchase can be found here.

A hedge fund recently bought a new stake in Adaptimmune Therapeutics PLC – stock. Marshall Wace LLP acquired a new stake in shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 140,983 shares of the company’s stock, valued at approximately $1,700,000. Marshall Wace LLP owned 0.20% of Adaptimmune Therapeutics PLC – at the end of the most recent reporting period.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.